Needham & Company Sees 150% Upside in Cytokinetics (CYTK) after Expanded Amgen (AMGN) Deal
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $74.13 +0.93%
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company's Chad Messer boosted his price target on Buy-rated Cytokinetics (NASDAQ: CYTK) from $2.50 to $3.50 Thursday, following expansion of the Amgen (NASDAQ: AMGN) deal for heart failure drug Omecamtiv in Japan.
"While a positive event in and of itself, we believe the timing of the deal reflects Amgen's confidence in the program and increases our confidence in the outcome of the ongoing Phase IIb ATOMIC-HF study, which should report out as early as this month," Messer said.
The ATOMIC-HF study could be a major driver for the stock, according to the analysts.
"Enrollment in ATOMIC is complete and partner Amgen is working to lock the study
database. Top line data is expected mid-year. The primary endpoint is the reduction of dyspnea (shortness of breath) during a 48 hour infusion, but we believe as long as Amgen concludes there is sufficient efficacy to support starting a pivotal trial, CYTK shares should stage a significant rally. In January Amgen initiated the COSMIC-HF study testing 3 oral doses of omecamtiv. We continue to expect data from ATOMIC and COSMIC to inform a pivotal iv-to-oral study in 2014."
For an analyst ratings summary and ratings history on Cytokinetics click here. For more ratings news on Cytokinetics click here.
Shares of Cytokinetics closed at $1.40 yesterday.
"While a positive event in and of itself, we believe the timing of the deal reflects Amgen's confidence in the program and increases our confidence in the outcome of the ongoing Phase IIb ATOMIC-HF study, which should report out as early as this month," Messer said.
The ATOMIC-HF study could be a major driver for the stock, according to the analysts.
"Enrollment in ATOMIC is complete and partner Amgen is working to lock the study
database. Top line data is expected mid-year. The primary endpoint is the reduction of dyspnea (shortness of breath) during a 48 hour infusion, but we believe as long as Amgen concludes there is sufficient efficacy to support starting a pivotal trial, CYTK shares should stage a significant rally. In January Amgen initiated the COSMIC-HF study testing 3 oral doses of omecamtiv. We continue to expect data from ATOMIC and COSMIC to inform a pivotal iv-to-oral study in 2014."
For an analyst ratings summary and ratings history on Cytokinetics click here. For more ratings news on Cytokinetics click here.
Shares of Cytokinetics closed at $1.40 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherent (COHR) PT Raised to $420 at Needham
- Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
- H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, Hot CommentsRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
